BG107513A - Кумаринови производни със сомт инхибираща активност - Google Patents

Кумаринови производни със сомт инхибираща активност Download PDF

Info

Publication number
BG107513A
BG107513A BG107513A BG10751303A BG107513A BG 107513 A BG107513 A BG 107513A BG 107513 A BG107513 A BG 107513A BG 10751303 A BG10751303 A BG 10751303A BG 107513 A BG107513 A BG 107513A
Authority
BG
Bulgaria
Prior art keywords
alkyl
cooh
halogen
compound
substituents
Prior art date
Application number
BG107513A
Other languages
Bulgarian (bg)
English (en)
Inventor
Jarmo Pystynen
Martti Ovaska
Jukka Vidgren
Timo Lotta
Marjo Yliperttula-Ikonen
Original Assignee
Orion Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Corporation filed Critical Orion Corporation
Publication of BG107513A publication Critical patent/BG107513A/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/76—Benzo[c]pyrans

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
BG107513A 2000-07-03 2003-01-31 Кумаринови производни със сомт инхибираща активност BG107513A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20001593A FI20001593A (fi) 2000-07-03 2000-07-03 Comt-entsyymiõ inhiboivaa aktiivisuutta omaavia kumariinijohdannaisia
PCT/FI2001/000613 WO2002002548A1 (fr) 2000-07-03 2001-06-28 Derives de coumarine ayant une activite d'inhibition de la comt

Publications (1)

Publication Number Publication Date
BG107513A true BG107513A (bg) 2003-06-30

Family

ID=8558717

Family Applications (1)

Application Number Title Priority Date Filing Date
BG107513A BG107513A (bg) 2000-07-03 2003-01-31 Кумаринови производни със сомт инхибираща активност

Country Status (27)

Country Link
US (1) US6951870B2 (fr)
EP (1) EP1301503B1 (fr)
JP (1) JP4851051B2 (fr)
KR (1) KR20030040225A (fr)
CN (1) CN1199963C (fr)
AT (1) ATE260268T1 (fr)
AU (2) AU2001272597B9 (fr)
BG (1) BG107513A (fr)
BR (1) BR0111969A (fr)
CA (1) CA2414787C (fr)
DE (1) DE60102161T2 (fr)
DK (1) DK1301503T3 (fr)
EE (1) EE200300008A (fr)
ES (1) ES2215919T3 (fr)
FI (1) FI20001593A (fr)
HU (1) HUP0301706A3 (fr)
IL (2) IL153352A0 (fr)
MX (1) MXPA02012657A (fr)
NO (1) NO328699B1 (fr)
NZ (1) NZ523121A (fr)
PL (1) PL359068A1 (fr)
PT (1) PT1301503E (fr)
RU (1) RU2282627C2 (fr)
SK (1) SK18452002A3 (fr)
TR (1) TR200400802T4 (fr)
WO (1) WO2002002548A1 (fr)
ZA (1) ZA200210161B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR846401A0 (en) * 2001-10-25 2001-11-15 Novogen Research Pty Ltd 6-Hydroxy isoflavones, derivatives and medicaments involving same
AU2002951833A0 (en) * 2002-10-02 2002-10-24 Novogen Research Pty Ltd Compositions and therapeutic methods invloving platinum complexes
AU2003265737B2 (en) * 2002-10-02 2008-10-16 Novogen Research Pty Ltd Combination chemotherapy compositions and methods
CN1506359A (zh) * 2002-12-05 2004-06-23 �й�ҽѧ��ѧԺҩ���о��� 新的香豆素酰胺衍生物及其制法和其药物组合物与用途
NZ553834A (en) 2004-09-21 2010-03-26 Novogen Res Pty Ltd 7-hydroxy-3,4-diphenyl-chroman and chromene derivatives
US8080675B2 (en) 2004-09-21 2011-12-20 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
MY148644A (en) * 2005-07-18 2013-05-15 Orion Corp New pharmaceutical compounds
EP1917245A1 (fr) 2005-08-21 2008-05-07 Abbott GmbH & Co. KG Composes heterocycliques et leur utilisation en tant que partenaires de liaison des recepteurs 5-ht5
WO2007124617A1 (fr) * 2006-04-28 2007-11-08 Institute Of Mataria Medica, Chinese Academy Of Medical Sciences Dérivés de coumarine, leurs procédés de préparation, compositions pharmaceutiques et utilisations
ES2343347B2 (es) * 2009-01-27 2011-12-07 Universidade De Santiago De Compostela Uso de derivados de 3-fenilcumarinas 6-sustituidas y preparacion de nuevos derivados.
WO2012061413A2 (fr) 2010-11-01 2012-05-10 Marshall Edwards, Inc. Compositions d'isoflavonoïdes et méthodes de traitement du cancer
TWI638802B (zh) 2012-05-24 2018-10-21 芬蘭商奧利安公司 兒茶酚ｏ－甲基轉移酶活性抑制化合物
MX2017010002A (es) 2015-02-02 2018-02-09 Mei Pharma Inc Terapias de combinacion.
JP7007292B2 (ja) * 2015-12-18 2022-02-10 ケスター、ヒューバート 薬剤としての使用のため、特にパーキンソン病の治療のための新規二環式化合物
CN107868069A (zh) * 2017-10-31 2018-04-03 山东新华制药股份有限公司 7‑羟基‑8‑甲基‑6‑硝基‑2‑氧‑2h‑苯并吡喃‑3‑羧酸的制备工艺

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3973608A (en) 1973-08-01 1976-08-10 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Microbial production of certain isoflavones
JPS5035393A (fr) * 1973-08-01 1975-04-04
US5236952A (en) * 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
US5283352A (en) * 1986-11-28 1994-02-01 Orion-Yhtyma Oy Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same
GB8816519D0 (en) 1987-07-23 1988-08-17 Ici Plc Antibiotic compounds
HUT63843A (en) 1992-02-13 1993-10-28 Biosignal Kutato Fejlesztoe Kf Process for producing new kumarin derivatives and their analogs inhibiting mammal cell proliferation and tumour growth, as well as pharmaceutical comkpositions comprising such compounds
JP3166094B2 (ja) * 1993-09-08 2001-05-14 森永乳業株式会社 クマリン誘導体及びそれらの用途
JPH0892157A (ja) 1994-05-02 1996-04-09 F Hoffmann La Roche Ag プルプロガリン誘導体
GB9626472D0 (en) 1996-12-20 1997-02-05 Aperia Anita C New use of comt inhibitors

Also Published As

Publication number Publication date
EP1301503A1 (fr) 2003-04-16
ES2215919T3 (es) 2004-10-16
US20030186975A1 (en) 2003-10-02
RU2282627C2 (ru) 2006-08-27
EP1301503B1 (fr) 2004-02-25
JP4851051B2 (ja) 2012-01-11
WO2002002548A1 (fr) 2002-01-10
BR0111969A (pt) 2003-07-01
HUP0301706A3 (en) 2005-12-28
AU7259701A (en) 2002-01-14
PT1301503E (pt) 2004-06-30
SK18452002A3 (sk) 2004-04-06
DE60102161D1 (de) 2004-04-01
PL359068A1 (en) 2004-08-23
AU2001272597B2 (en) 2005-07-21
DE60102161T2 (de) 2004-09-16
EE200300008A (et) 2004-08-16
KR20030040225A (ko) 2003-05-22
FI20001593A0 (fi) 2000-07-03
NO20026095D0 (no) 2002-12-18
CN1440399A (zh) 2003-09-03
US20040110750A9 (en) 2004-06-10
IL153352A (en) 2009-05-04
JP2004502684A (ja) 2004-01-29
NZ523121A (en) 2004-08-27
TR200400802T4 (tr) 2004-07-21
HUP0301706A2 (hu) 2003-09-29
ATE260268T1 (de) 2004-03-15
FI20001593A (fi) 2002-01-04
NO20026095L (no) 2003-03-03
CN1199963C (zh) 2005-05-04
DK1301503T3 (da) 2004-06-28
NO328699B1 (no) 2010-04-26
CA2414787C (fr) 2010-12-14
ZA200210161B (en) 2004-03-15
US6951870B2 (en) 2005-10-04
AU2001272597B9 (en) 2005-08-11
IL153352A0 (en) 2003-07-06
CA2414787A1 (fr) 2002-01-10
MXPA02012657A (es) 2003-05-14

Similar Documents

Publication Publication Date Title
BG107513A (bg) Кумаринови производни със сомт инхибираща активност
JPH09510704A (ja) Ｐａｒｐ（ａｄｐ−リボシルトランスフェラーゼ、ａｄｐｒｔ）および修復酵素として有用なベンズアミド類似体
EP2305246A1 (fr) Inhibiteurs du facteur de nécrose tumorale
SK46599A3 (en) Use of condensated (hetaryl-substituted) 1-benzal-3-pyrazol derivates for treating special diseases of the cardiovascular and the central nervous systems
JPH11510154A (ja) ベンズイミダゾール化合物
AU2001272597A1 (en) Coumarin derivatives with COMT inhibiting activity
AU2012327209A1 (en) Compositions and methods for the modulation of specific amidases for N-acylethanolamines for use in the therapy of inflammatory diseases
KR20150103034A (ko) 피리돈 유도체 및 바이러스 질환의 치료, 개선 또는 예방에서의 이의 용도
KR100545474B1 (ko) 페닐아미노알킬카르복실산 유도체 및 그것을 함유하는의약조성물
JP5213961B2 (ja) アミノ酸誘導体
JPH02124884A (ja) Ｎ―置換アミド誘導体
WO2013064714A1 (fr) Composés pharmaceutiques inhibant p38 et leurs applications
JP2001511799A (ja) オキシド−スクアレンシクラーゼ阻害剤として有用なヘテロ環式化合物
BG107219A (bg) Терапевтично приложими нови соли на сск инхибитори, методи за тяхното получаване и фармацевтични състави, които ги съдържат
JP3166093B2 (ja) クマリン誘導体及びそれらの用途
EP1844775A1 (fr) Agent thérapeutique pour le traitement de l'herpès génital
JP4976499B2 (ja) キマーゼ阻害剤としてのビニル酸誘導体
CN109824574B (zh) 吲哚-3-甲酰胺类化合物及其应用
JPH11509533A (ja) Ｎｍｄａ受容体拮抗薬としての多環式アルカロイド誘導体
KR100832750B1 (ko) Ｎ-페닐아마이드 유도체를 함유하는 허혈성 질환의 예방또는 치료용 조성물
EP0395526A1 (fr) Nouveaux dérivés benzothiazolinoniques, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
EP0623608B1 (fr) Derive de benzopyrane, production de ce derive et preparation pharmaceutique le contenant comme ingredient actif
KR100832751B1 (ko) Ｎ-페닐아마이드 유도체 및 이의 제조방법
JP2006512378A (ja) ３−置換−４−アリールキノリン−２−オン誘導体のアトロプ異性体
RU2233279C1 (ru) СОЛИ 9-ω-АРИЛОКСИАЛКИЛ-2,3-ДИГИДРОИМИДАЗО[1,2-А]БЕНЗИМИДАЗОЛА, ОБЛАДАЮЩИЕ МЕСТНОАНЕСТЕЗИРУЮЩИМ ДЕЙСТВИЕМ